Philip Morris International's Vectura Fertin Pharma Announces Agreement For Sale Of Vectura Group To Molex; Terms Not Disclosed
Author: Benzinga Newsdesk | September 17, 2024 09:16am
Vectura Fertin Pharma, Inc., an affiliate of Philip Morris International Inc. (PMI) (NYSE:PM), today announces the sale of its subsidiary Vectura Group Ltd. (Vectura) to Molex Asia Holdings Ltd., and the establishment of master service agreements to develop Vectura Fertin Pharma's inhaled therapeutics proprietary pipeline. Vectura will be operated by Phillips Medisize, a Molex company. The sale includes upfront cash consideration of GBP 150 million, subject to customary purchase price adjustments, and potential deferred payments of up to GBP 148 million. The transaction is subject to customary closing conditions, including regulatory approval.
Posted In: PM